Dimethyl Fumarate for the Treatment of Intracerebral Hemorrhage

Summary

The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in alleviating PHE and neurologic deficits in patients with ICH.

Timeline

Start

2021-06-01

Primary completion

2021-12-31

Completion

2021-12-31

Drugs

Indications